IP Library Granted Patent US 7,732,163
Granted Patent B2
US 7,732,163 · App. 10/652,846 · Granted Jun 8, 2010

Extracellular serine protease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,732,163
App. No.
10/652,846
Granted
Jun 8, 2010
Kind
B2
Abstract

The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.

Claims (4)

1. An isolated DNA that differs from the nucleic acid sequence of SEQ ID NO: 6 due to inclusion of an intron sequence between exon 2 and exon 3 of SEQ ID NO: 6, said DNA encoding a TADG-14 protein variant with an amino acid sequence shown in SEQ ID NO: 75.

2. A vector capable of expressing the DNA of claim 1 , wherein said vector is adapted for expression in a cell and comprises regulatory elements necessary for expressing said DNA in said cell.

3. A host cell transfected with the vector of claim 2 , wherein said vector expresses a TADG-14 protein variant with the amino acid sequence shown in SEQ ID NO: 75.

4. The host cell of claim 3 , wherein said cell is a bacterial cell, a mammalian cell, a plant cell or an insect cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2017
From: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 044037/0496 →